Please login to the form below

Not currently logged in
Email:
Password:

Study: Gardasil better value than Cervarix

Gardasil, the human papillomavirus vaccine developed by Sanofi and MSD, may be a more cost-effective option than GlaxoSmithKline's Cervarix in the UK according to a report

Gardasil, the human papillomavirus (HPV) vaccine developed by Sanofi and MSD, may be a more cost-effective option than GlaxoSmithKline's (GSK) Cervarix in the UK according to a report in the British Medical Journal (BMJ).

Data from the study suggest that Gardasil, which protects against the HPV strains that cause both genital warts and cervical cancer, may have an advantage over Cervarix, which protects only against cervical cancer, in reducing healthcare costs and quality of life years (QALYs) lost.

The Department of Health (DH) in England and Wales picked Cervarix as the cheaper option to offer young girls in the UK to protect against HPV in 2008.

The NHS list price indicates Cervarix costs £80.50 per dose, while Gardasil is £88.50 per dose.

The study measured incremental cost-effectiveness ratios in the UK for both vaccines, however, with results recommending that Cervarix would need to be £19 to £35 cheaper to match the cost-effectiveness of Gardasil.

In their conclusion, investigators commented that, although Gardasil may have an advantage in reducing healthcare costs, Cervarix may have an advantage in preventing death due to cancer.

There is 'considerable uncertainty' remaining about the differential benefit of the two vaccines, according to the study.

29th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics